Keros Therapeutics Insider Trades
NASDAQ: KROSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 6 · $75.77K
- Sales
- 17 · $540.78K
- Shares bought / sold
- 7.00K / 40.33K
- Net activity
- Net selling $465,009
Keros Therapeutics insider activity
Over the last 12 months, Keros Therapeutics insiders reported 31 transactions on SEC Form 4: 6 open-market purchases and 17 sales. Insiders bought $75,770 and sold $540,779 worth of stock, for net insider selling of $465,009. The largest seller was Cho Esther, with $123,731 in reported sales.
The most recent filing shows Newton Charles W. (Director) selling 491 shares at $10.83 on Nov 17, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put KROS's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
KROS insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Nov 17, 2026 | Prener AnneDirector | Sale | 142 | $1.57K | Form 4 |
| Nov 17, 2026 | Prener AnneDirector | Sale | 433 | $4.66K | Form 4 |
| Nov 17, 2026 | Newton Charles W.Director | Sale | 60 | $663 | Form 4 |
| Nov 17, 2026 | Newton Charles W.Director | Sale | 491 | $5.32K | Form 4 |
| Nov 12, 2026 | Prener AnneDirector | Sale | 574 | $5.62K | Form 4 |
| Aug 18, 2026 | Newton Charles W.Director | Sale | 551 | $5.68K | Form 4 |
| Aug 18, 2026 | Cho EstherChief Legal Officer | Sale | 4,485 | $46.15K | Form 4 |
| Aug 18, 2026 | Lerner Lorena RaquelChief Scientific Officer | Sale | 3,568 | $36.71K | Form 4 |
| Aug 18, 2026 | Tanini AnnitaCorp. Controller & VP, Finance | Sale | 1,224 | $12.59K | Form 4 |
| Aug 17, 2026 | BIENAIME JEAN JACQUESDirector | Buy | 1,000 | $10.27K | Form 4 |
| Jul 15, 2026 | BIENAIME JEAN JACQUESDirector | Buy | 1,000 | $10.61K | Form 4 |
| Jul 1, 2026 | Prener AnneDirector | Award | 13,786 | — | Form 4 |
| Jun 15, 2026 | BIENAIME JEAN JACQUESDirector | Buy | 1,000 | $10.19K | Form 4 |
| Jun 11, 2026 | Newton Charles W.Director | Sale | 550 | $5.52K | Form 4 |
| Jun 4, 2026 | Seth AlpnaDirector | Sale | 2,625 | $28.14K | Form 4 |
| Jun 4, 2026 | Knowles JuliusDirector | Sale | 2,625 | $28.17K | Form 4 |
| Jun 4, 2026 | Farzan NimaDirector | Sale | 2,625 | $28.17K | Form 4 |
| Jun 3, 2026 | Knowles JuliusDirector | Award | 7,142 | — | Form 4 |
| Jun 3, 2026 | BIENAIME JEAN JACQUESDirector | Award | 7,142 | — | Form 4 |
| Jun 3, 2026 | Farzan NimaDirector | Award | 7,142 | — | Form 4 |
| Jun 3, 2026 | GRAY MARY ANNDirector | Award | 7,142 | — | Form 4 |
| Jun 3, 2026 | Seth AlpnaDirector | Award | 7,142 | — | Form 4 |
| May 15, 2026 | BIENAIME JEAN JACQUESDirector | Buy | 1,000 | $10.58K | Form 4 |
| Apr 15, 2026 | BIENAIME JEAN JACQUESDirector | Buy | 1,000 | $11.70K | Form 4 |
| Apr 2, 2026 | Seehra JasbirCHIEF EXECUTIVE OFFICER | Option exercise | 55,000 | $16.50K | Form 4 |
| Mar 9, 2026 | Newton Charles W.Director | Award | 13,215 | — | Form 4 |
| Mar 9, 2026 | BIENAIME JEAN JACQUESDirector | Buy | 2,000 | $22.42K | Form 4 |
| Feb 19, 2026 | Seehra JasbirCHIEF EXECUTIVE OFFICER | Sale | 7,015 | $113.43K | Form 4 |
| Feb 18, 2026 | Regnante KeithCHIEF FINANCIAL OFFICER | Sale | 4,739 | $77.48K | Form 4 |
| Feb 18, 2026 | Cho EstherSVP, General Counsel | Sale | 4,745 | $77.58K | Form 4 |
| Feb 18, 2026 | Lerner Lorena RaquelChief Science Officer | Sale | 3,873 | $63.32K | Form 4 |
| Nov 21, 2025 | Knowles JuliusDirector | Disposition | 130,494 | $2.32M | Form 4 |
| Nov 21, 2025 | Knowles JuliusDirector | Disposition | 191,527 | $3.40M | Form 4 |
| Nov 21, 2025 | GORDON CARL LDirector | Disposition | 74,465 | $1.32M | Form 4 |
| Nov 21, 2025 | GORDON CARL LDirector | Disposition | 140,057 | $2.49M | Form 4 |
| Nov 21, 2025 | ORBIMED ADVISORS LLC & OrbiMed Capital GP VII LLC & OrbiMed Genesis GP LLCDirector | Disposition | 74,465 | $1.32M | Form 4 |
| Nov 21, 2025 | ORBIMED ADVISORS LLC & OrbiMed Capital GP VII LLC & OrbiMed Genesis GP LLCDirector | Disposition | 140,057 | $2.49M | Form 4 |
| Oct 15, 2025 | ADAR1 Capital Management, LLC & ADAR1 Partners, LP & ADAR1 Capital Management GP, LLC & Schneeberger Daniel10% Owner | Sale | 743,358 | $13.19M | Form 4 |
| Oct 15, 2025 | ADAR1 Capital Management, LLC & ADAR1 Partners, LP & ADAR1 Capital Management GP, LLC & Schneeberger Daniel10% Owner | Sale | 254,669 | $4.52M | Form 4 |
| Oct 15, 2025 | ADAR1 Capital Management, LLC & ADAR1 Partners, LP & ADAR1 Capital Management GP, LLC & Schneeberger Daniel10% Owner | Sale | 4,391,237 | $77.94M | Form 4 |
| Oct 15, 2025 | Pontifax Management 4 G.P. (2015) Ltd. & Pontifax (Israel) IV, L.P. & Pontifax (Cayman) IV L.P. & Pontifax (China) IV L.P. & Pontifax Late Stage Fund L.P. & Pontifax Late Stage GP Ltd. & Kariv Tomer & Nussbaum Ran10% Owner | Sale | 155,262 | $2.76M | Form 4 |
| Oct 15, 2025 | Pontifax Management 4 G.P. (2015) Ltd. & Pontifax (Israel) IV, L.P. & Pontifax (Cayman) IV L.P. & Pontifax (China) IV L.P. & Pontifax Late Stage Fund L.P. & Pontifax Late Stage GP Ltd. & Kariv Tomer & Nussbaum Ran10% Owner | Sale | 1,226,412 | $21.77M | Form 4 |
| Oct 15, 2025 | Pontifax Management 4 G.P. (2015) Ltd. & Pontifax (Israel) IV, L.P. & Pontifax (Cayman) IV L.P. & Pontifax (China) IV L.P. & Pontifax Late Stage Fund L.P. & Pontifax Late Stage GP Ltd. & Kariv Tomer & Nussbaum Ran10% Owner | Sale | 1,121,045 | $19.90M | Form 4 |
| Oct 15, 2025 | Pontifax Management 4 G.P. (2015) Ltd. & Pontifax (Israel) IV, L.P. & Pontifax (Cayman) IV L.P. & Pontifax (China) IV L.P. & Pontifax Late Stage Fund L.P. & Pontifax Late Stage GP Ltd. & Kariv Tomer & Nussbaum Ran10% Owner | Sale | 2,284,612 | $40.55M | Form 4 |
| Sep 3, 2025 | Seehra JasbirCHIEF EXECUTIVE OFFICER | Award | 90,500 | — | Form 4 |
| Jun 20, 2025 | ADAR1 Capital Management, LLC & ADAR1 Partners, LP & ADAR1 Capital Management GP, LLC & Schneeberger Daniel10% Owner | Option exercise | 200 | $14.00K | Form 4 |
| Jun 20, 2025 | ADAR1 Capital Management, LLC & ADAR1 Partners, LP & ADAR1 Capital Management GP, LLC & Schneeberger Daniel10% Owner | Option exercise | 1,400 | $98.00K | Form 4 |
| Jun 20, 2025 | ADAR1 Capital Management, LLC & ADAR1 Partners, LP & ADAR1 Capital Management GP, LLC & Schneeberger Daniel10% Owner | Option exercise | 100 | $6.00K | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4